HIMS – Sharp Sell-Off on Novo Nordisk Fallout. Overreaction?

Today, Hims & Hers Health HIMS plunged by –28%, breaking key support around $46.
The sell-off was triggered by news that Novo Nordisk terminated its partnership with HIMS over the promotion of compounded alternatives to Wegovy, calling it “unethical.”

🔍 Key Drivers of the Drop:
• Public fallout with Novo Nordisk
• Very high trading volume (87M+) – panic selling
• RSI and Stochastic both entered oversold zones
• Key technical support at $46 was lost

🧠 Is this already priced in?

Despite the controversy, HIMS remains a strong player in telehealth and personalized treatments.
Their model isn’t solely dependent on this partnership. Investors may be overreacting.
📌 Idea: Rebound from panic-driven drop
• Entry zone: $45–46
• Target 1: $55
• Target 2: $65 (retest previous highs)
• Stop loss: $40

💬 Watch for official statements from HIMS and updates on new partnerships.